当前位置:首页 - 行情中心 - 贝瑞基因(000710) - 财务分析 - 利润表

贝瑞基因

(000710)

  

流通市值:47.27亿  总市值:51.12亿
流通股本:3.27亿   总股本:3.54亿

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入217,759,068.081,078,165,273.94822,664,528.62551,776,302.07
营业收入217,759,068.081,078,165,273.94822,664,528.62551,776,302.07
二、营业总成本214,518,555.651,072,541,450.25765,979,082.06508,721,669.59
营业成本110,008,040.12572,909,344.39406,324,355.34263,774,077.25
税金及附加414,696.2511,236,018.576,391,977.925,027,568.68
销售费用47,819,719.97236,830,171.84171,214,504.94118,094,609.35
管理费用33,141,322.58148,723,794.38119,317,330.3277,472,664.04
研发费用21,653,803.4795,419,662.2258,453,739.739,768,904.04
财务费用1,480,973.267,422,458.854,277,173.844,583,846.23
其中:利息费用2,209,183.919,831,402.96-6,392,136.14
其中:利息收入-900,869.893,522,477.58-1,845,526.9
加:公允价值变动收益-2,276,101.9-132,165.22-2,230,529.83-70,132.47
加:投资收益954,578.63-14,553,527.69-6,798,926.38-5,041,657.7
资产处置收益-14,866.731,739,687.324,598,331.9629,106.52
资产减值损失(新)--28,078,288.63--
信用减值损失(新)-5,459,820.52-132,930,004.56-26,450,355.96-17,453,976.35
其他收益425,716.911,717,510.771,542,459.111,170,329.93
营业利润平衡项目0000
四、营业利润-3,129,981.18-166,612,964.3227,346,425.4621,688,302.41
加:营业外收入2,922.26258,807.15234,871.58224,873.34
减:营业外支出618,144.784,403,254.131,284,017.731,095,412.59
利润总额平衡项目0000
五、利润总额-3,745,203.7-170,757,411.326,297,279.3120,817,763.16
减:所得税费用1,894,516.7317,417,622.9812,352,762.318,748,419.34
六、净利润-5,639,720.43-188,175,034.2813,944,51712,069,343.82
持续经营净利润-5,639,720.43-188,175,034.2813,944,51712,069,343.82
归属于母公司股东的净利润-6,462,206.12-192,428,499.7310,385,508.929,262,843.84
少数股东损益822,485.694,253,465.453,559,008.082,806,499.98
(一)基本每股收益-0.02-0.540.030.03
(二)稀释每股收益-0.02-0.540.030.03
八、其他综合收益-814,304.195,461,696.08-480,248.25908,278.13
归属于母公司股东的其他综合收益-669,245.914,595,883.99-332,858.02573,313.98
九、综合收益总额-6,454,024.62-182,713,338.213,464,268.7512,977,621.95
归属于母公司股东的综合收益总额-7,131,452.03-187,832,615.7410,052,650.99,836,157.82
归属于少数股东的综合收益总额677,427.415,119,277.543,411,617.853,141,464.13
公告日期2025-04-282025-04-252024-10-292024-08-23
审计意见(境内)标准无保留意见
TOP↑